Drug-Eluting Stents Market to Reach US$ 14.2 Bn by 2035, Driven by Technological Advancements and Cardiovascular Disease Burden

The global drug-eluting stents (DES) market was valued at US$ 7.7 Bn in 2024 and is projected to surpass US$ 14.2 Bn by 2035, expanding at a CAGR of 5.7% during the forecast period from 2025 to 2035, according to a new market report published by Transparency Market Research Inc. Increasing prevalence of cardiovascular diseases (CVDs), rising demand for minimally invasive cardiac procedures, and technological advancements in drug and stent materials are expected to propel market growth.

Get Sample PDF Brochure from here: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=30632

Analysts' Viewpoint

The drug-eluting stents market is undergoing rapid transformation, driven by a surge in CVD incidence and growing preference for less-invasive interventions. The continuous evolution in polymer-based drug delivery, biocompatible coatings, and bioabsorbable scaffolds has expanded therapeutic use, improving patient outcomes and reducing repeat interventions.

Furthermore, government reimbursement programs, expanding healthcare access in developing countries, and innovation in biodegradable polymers and second-generation drugs are anticipated to reinforce the industry outlook. Market leaders are also focusing on emerging economies, where the demand for coronary intervention procedures is rising steadily.

Market Overview

Drug-eluting stents (DES) are advanced coronary stents coated with medication to prevent restenosis, the re-narrowing of arteries after angioplasty. The drug coating is gradually released into the arterial wall, preventing excessive tissue growth, improving vessel patency, and reducing the need for repeat procedures.

DES have become standard in percutaneous coronary interventions (PCI) due to their superior performance over bare-metal stents (BMS). With the global CVD burden increasing and healthcare infrastructure improving in emerging markets, the DES market is set for robust growth.

Key Market Drivers

Introduction of Advanced Drug-Eluting Stents
Modern DES feature biocompatible and bioresorbable materials that reduce inflammation and thrombosis risks. Innovations in polymer science have enabled precise drug-release control, resulting in more effective treatment of coronary artery disease. Next-generation DES are also showing promise in treating complex vascular anatomies, further expanding their clinical adoption.

Rising Prevalence of Cardiovascular Disease
According to WHO, CVDs remain the leading cause of death globally, responsible for nearly 18 million deaths per year. Risk factors such as aging, sedentary lifestyles, hypertension, and diabetes continue to drive the demand for efficient cardiovascular interventions. DES offer a minimally invasive and cost-effective treatment alternative for patients needing revascularization.

Segment Insights

By Material

Polymer-based stents dominate the market due to their ability to regulate drug release and enhance biocompatibility.
Biodegradable polymers eliminate long-term complications and reduce the need for prolonged anti-platelet therapy.
Metal-based stents like cobalt-chromium and stainless steel remain relevant for their durability and support but are being gradually replaced by advanced polymeric options.

By Drug

Sirolimus, Everolimus, Paclitaxel, and Zotarolimus are commonly used drugs for preventing cell proliferation post-stenting.
Everolimus-based DES are witnessing growing preference for their safety and efficacy profiles.

By Application

Coronary Artery Disease (CAD) remains the largest application area, with DES playing a central role in PCI procedures.
Peripheral Artery Disease (PAD) applications are also expanding, thanks to miniaturized stent designs and improved deployment systems.

By End-user

Hospitals are the leading end-users due to the high volume of cardiac procedures performed.
Ambulatory Surgical Centers (ASCs) are witnessing increased DES use with the trend toward outpatient interventions.

Regional Outlook

North America dominated the drug-eluting stents market in 2024, driven by:

High prevalence of CVDs and aging population
Advanced healthcare infrastructure
Rapid adoption of next-gen interventional cardiology solutions
Robust R&D ecosystem and strong FDA pipeline for innovative stent products
Asia Pacific is projected to be the fastest-growing region from 2025 to 2035:

Large target population
Rapid urbanization and increasing lifestyle-related CVDs
Expanding private healthcare infrastructure in China, India, and Southeast Asia

Competitive Landscape

The global DES market is highly consolidated, with key players focusing on strategic acquisitions, geographic expansion, and R&D investments to maintain their market leadership. Innovation in biodegradable platforms, dual-drug DES, and targeted therapy combinations is a priority area for players.

Key Companies Profiled

Abbott Laboratories
Boston Scientific Corporation
Medtronic plc
B. Braun Melsungen AG
Biosensors International Group, Ltd.
AlviMedica
Cook Medical Inc.
Elixir Medical Corp.
Lepu Medical Technology Co., Ltd.
Eurocor GmbH
Shandong JW Medical Systems LTD.
OrbusNeich Medical Company Limited
Shanghai MicroPort Medical Co., Ltd.
Sino Medical Sciences Technology Inc.

Recent Developments

June 2024 - Elixir Medical received FDA Breakthrough Device Designation for its DynamX Sirolimus-Eluting Bioadaptor System, which restores natural coronary motion and improves luminal diameter.
May 2024 - Abbott launched the XIENCE Sierra Everolimus-eluting stent in India. The stent is CE-marked and represents a key addition to Abbott's flagship XIENCE portfolio.

Market Segmentation

By Material

Metal (Stainless Steel, Cobalt-Chromium, Nitinol, Others)
Polymer (Non-biodegradable, Biodegradable)

By Drug

Sirolimus
Paclitaxel
Zotarolimus
Everolimus
Others

By Application

Coronary Artery Disease (CAD)
Peripheral Artery Disease (PAD)
Others

By End-user

Hospitals
Ambulatory Surgical Centers
Others

Buy this Premium Research Report:

https://www.transparencymarketresearch.com/checkout.php?rep_id=30632<ype=S

Explore Latest Research Reports by Transparency Market Research:

Echocardiography Market- https://www.transparencymarketresearch.com/echocardiography-market-report.html

Continuous Glucose Monitoring Market- https://www.transparencymarketresearch.com/continuous-glucose-monitoring.html

Brain Computer Interface Market- https://www.transparencymarketresearch.com/brain-computer-interface-market.html

Home Healthcare Market- https://www.transparencymarketresearch.com/home-healthcare-market.html

Medical Imaging Equipment Market- https://www.transparencymarketresearch.com/medical-imaging-equipment-market-report.html

Contact Us:
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

This release was published on openPR.